| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | ALB |
| Uniprot No | P02768 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-609aa |
| 氨基酸序列 | DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFA KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL |
| 预测分子量 | 67 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ALB重组蛋白的3篇参考文献示例(文献为虚构示例，仅供格式参考)：
---
1. **文献名称**: *Recombinant human albumin: A versatile drug carrier for targeted therapeutics*
**作者**: Smith A, et al.
**摘要**: 本研究探讨重组人血清白蛋白(rHSA)作为药物载体的应用，通过基因工程技术修饰其表面结合位点，显著提高了抗癌药物的靶向性和体内半衰期，为肿瘤治疗提供了新策略。
---
2. **文献名称**: *High-yield production of recombinant albumin in Pichia pastoris and its structural characterization*
**作者**: Zhang L, et al.
**摘要**: 报道了一种利用毕赤酵母高效表达重组白蛋白的工艺，通过优化发酵条件使产量提升至5 g/L，并通过质谱和圆二色谱验证了其与天然白蛋白的结构一致性。
---
3. **文献名称**: *Albumin-based nanoparticles for gene delivery: Stability and biocompatibility evaluation*
**作者**: Gupta R, et al.
**摘要**: 开发了重组白蛋白纳米颗粒用于基因递送系统，实验表明其能有效保护DNA免受酶解，并在体内外展现出低毒性和高转染效率，具有潜在临床应用价值。
---
(注：以上文献信息为模拟生成，非真实存在。实际研究中请通过PubMed、Web of Science等平台检索真实文献。)
**Background of Recombinant Albumin (ALB)**
Albumin, a multifunctional plasma protein, is the most abundant protein in human blood, constituting approximately 50-60% of total serum protein. Naturally produced by the liver, human serum albumin (HSA) plays critical roles in maintaining oncotic pressure, transporting hormones, fatty acids, and drugs, and acting as an antioxidant. Traditionally, HSA for medical or research use was isolated from human blood, raising concerns over supply limitations, batch-to-batch variability, and potential pathogen contamination.
To address these challenges, recombinant albumin (rALB) emerged as a safer and scalable alternative. Produced via genetic engineering, rALB is synthesized by inserting the human albumin gene into expression systems such as bacteria, yeast, mammalian cells, or plants. Common platforms include *Pichia pastoris* and Chinese hamster ovary (CHO) cells, which enable post-translational modifications similar to native HSA. This technology ensures high purity, consistency, and reduced immunogenicity, making rALB ideal for pharmaceutical applications.
Recombinant albumin is widely utilized in drug formulations (e.g., as a stabilizer or excipient), vaccines, cell culture media, and regenerative medicine. Its biocompatibility and non-toxic nature also support its use in nanoparticle drug delivery and diagnostic tools. Recent advancements focus on optimizing expression yields, cost efficiency, and functional modifications (e.g., fusion proteins). Despite progress, challenges like achieving native-like structural fidelity and large-scale production costs remain areas of active research.
Overall, recombinant albumin represents a pivotal innovation in biopharmaceuticals, combining safety, sustainability, and versatility to meet growing industrial and therapeutic demands.
×
